Seres Therapeutics (MCRB)
Develops oral bacterial consortia for infection, immune, and inflammatory conditions.
$5.54
Pre-market+0.03 (+0.54%)
At close$5.51(+6.37%)
Something off on this page? Send us feedback.
Next report
Nov 4, 2026
in 62 days
EPS estimate
−$1.01
Revenue estimate
$6.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.32−$2.24−$2.27$0.94−$1.89−$2.08$0.47Pending
Estimate−$0.17−$0.67−$2.72$0.05−$2.39−$1.88−$2.18−$1.01
Surprise−88.2%−234.3%+16.5%+1,780.0%+20.9%−10.6%+121.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———$351.0K$438.0K$358.0K$736.0KPending
Estimate$12.5M$10.0M$5.9M$7.8M$5.3M$358.0K$179.0K$6.4M
Surprise———−95.5%−91.7%0.0%+311.2%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.01 | — | — |
| Aug 2026 | −$2.18 | $0.47 | +121.6% |
| May 2026 | −$1.88 | −$2.08 | −10.6% |
| Mar 2026 | −$2.39 | −$1.89 | +20.9% |
| Nov 2025 | $0.05 | $0.94 | +1,780.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$1.01 | — | — | $6.4M | — | — | — |
| Aug 5, 2026 | −$2.18 | $0.47 | +121.6% | $179.0K | $736.0K | +311.2% | −4.6% |
| May 5, 2026 | −$1.88 | −$2.08 | −10.6% | $358.0K | $358.0K | 0.0% | +6.7% |
| Mar 12, 2026 | −$2.39 | −$1.89 | +20.9% | $5.3M | $438.0K | −91.7% | −4.6% |
| Nov 5, 2025 | $0.05 | $0.94 | +1,780.0% | $7.8M | $351.0K | −95.5% | +9.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 5, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 7, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 4, 2021 | |||||||
| Mar 2, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Jul 28, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 2, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 6, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 16, 2017 | |||||||
| Nov 10, 2016 | |||||||
| Aug 11, 2016 | |||||||
| May 16, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Nov 10, 2015 | |||||||
| Aug 10, 2015 | |||||||